Emboline's Game-Changing PROTECT H2H Trial Results Herald New Era in TAVR Embolic Protection

Emboline's Breakthrough in Embolic Protection with PROTECT H2H Trial Results

Emboline, Inc., a pioneering company in the field of medical technology, has made headlines with the announcement of positive results from its pivotal PROTECT H2H clinical trial. This critical study evaluated the Emboliner® Embolic Protection System in patients undergoing transcatheter aortic valve replacement (TAVR). The results were presented as a late-breaking clinical trial at the American College of Cardiology's (ACC) Annual Scientific Session at ACC 2026, marking a significant achievement for the company and the field of cardiovascular interventions.

Key Highlights from the PROTECT H2H Trial

The PROTECT H2H trial was notable for being the first randomized Investigational Device Exemption (IDE) trial of an embolic protection device within the TAVR patient population. Completing all primary and secondary safety and efficacy endpoints demonstrates a major advancement in the category of embolic protection technology.

In total, 522 patients diagnosed with severe aortic stenosis participated in this trial. They were randomized into two groups, one receiving the Emboliner system and the other the Sentinel CPS device from Boston Scientific. The study began in May 2023, with patient follow-up concluding in December 2025, bringing forward compelling clinical data that outlines Emboliner's effectiveness.

Statistical Outcomes

1. Primary Endpoint Achievement: The study's main goal aimed at determining the combined safety and efficacy outcomes (30-day Major Adverse Cardiac and Cerebrovascular Events, MACCE). The Emboliner system showed a rate of 4.5% versus 5.0% for the control device, achieving statistical non-inferiority with a p-value of 0.0004.

2. Stroke Rate Comparison: In assessing secondary endpoints, the incidence of stroke after 30 days was 2.0% for Emboliner compared to 2.1% for the control, also achieving non-inferiority (p = 0.0001).

3. Debris Capture Success: Most impressively, the Emboliner outperformed its competitor in capturing debris, with statistical superiority demonstrated by a capture of 93 particles (≥150µm) compared to just 31 for the control device (p < 0.0001).

4. Technical Success Rates: Once more, Emboliner led in procedural success rates, showing a striking 95.9% technical success as opposed to 87.1% for the control device (p = 0.0005).

Clinical Implications and Experts’ Opinions

According to Scott Russell, President and CEO of Emboline, these results are pivotal, confirming their longstanding belief that embolic protection in TAVR must address the entire spectrum of embolic risk. He emphasized how the design of the Emboliner seeks to capture and remove debris efficiently while being easy for operators to adopt in clinical settings.

Dr. Tamim Nazif, Director of Clinical Research in Cardiology at Columbia University and a co-principal investigator for the trial, remarked that the liberation of embolic debris is a common concern in TAVR. The study's findings indicate a robust and user-friendly solution through the Emboliner, which demonstrates compatibility in clinical workflows.

Similarly, Dr. Adam B. Greenbaum, co-director at the Emory Structural Heart and Valve Center, highlighted the necessity of comprehensive embolic protection solutions as TAVR becomes more prevalent in diverse and complex patient groups. He noted the compelling nature of the trial data that supports a need for advanced preventative measures against embolic risks.

Looking Ahead: Regulatory Submission and Market Potential

With these encouraging results, Emboline is setting its sights on regulatory submission and anticipates market readiness for the Emboliner system. The device, currently under investigation and not available for commercial sale, offers the potential to transform embolic protection in structural heart interventions.

In conclusion, the PROTECT H2H trial results signify a breakthrough not just for Emboline, but for the field of cardiology, providing hope for improved outcomes in patients undergoing TAVR procedures by offering a more effective embolic protection solution.